You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTubocurarine
Accession NumberDB01199  (APRD00176)
TypeSmall Molecule
GroupsApproved
DescriptionA neuromuscular blocker and active ingredient in curare; plant based alkaloid of Menispermaceae. [PubChem]
Structure
Thumb
Synonyms
(+)-tubocurarine
7',12'-Dihydroxy-6,6'-dimethoxy-2,2',2'-trimethyltubocuraranium
d-tubocurarine
Tubocurarin
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Tubocurarine Chloride Inj 3mg/mlsolution3 mgintravenousAbbott Laboratories, Limited1951-12-312008-06-06Canada
Tubocurarine Chloride Inj 3mg/ml USPsolution3 mgintramuscular; intravenousAbbott Laboratories, Limited1985-12-312008-06-06Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
TubarineNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Tubocurarine chloride pentahydrate
6989-98-6
Thumb
  • InChI Key: WMIZITXEJNQAQK-GGDSLZADSA-N
  • Monoisotopic Mass: 770.2948159
  • Average Mass: 771.73
DBSALT000238
Categories
UNIIW9YXS298BM
CAS number57-95-4
WeightAverage: 609.7312
Monoisotopic: 609.296462054
Chemical FormulaC37H41N2O6
InChI KeyInChIKey=JFJZZMVDLULRGK-URLMMPGGSA-O
InChI
InChI=1S/C37H40N2O6/c1-38-14-12-24-19-32(42-4)33-21-27(24)28(38)16-22-6-9-26(10-7-22)44-37-35-25(20-34(43-5)36(37)41)13-15-39(2,3)29(35)17-23-8-11-30(40)31(18-23)45-33/h6-11,18-21,28-29H,12-17H2,1-5H3,(H-,40,41)/p+1/t28-,29+/m0/s1
IUPAC Name
(1S,16R)-9,21-dihydroxy-10,25-dimethoxy-15,15,30-trimethyl-7,23-dioxa-15,30-diazaheptacyclo[22.6.2.2³,⁶.1⁸,¹².1¹⁸,²².0²⁷,³¹.0¹⁶,³⁴]hexatriaconta-3,5,8(34),9,11,18(33),19,21,24,26,31,35-dodecaen-15-ium
SMILES
[H][C@@]12CC3=CC=C(OC4=C5C(CC[N+](C)(C)[C@]5([H])CC5=CC(OC6=C(OC)C=C(CCN1C)C2=C6)=C(O)C=C5)=CC(OC)=C4O)C=C3
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzylisoquinolines. These are organic compounds containing an isoquinoline to which a benzyl group is attached.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassIsoquinolines and derivatives
Sub ClassBenzylisoquinolines
Direct ParentBenzylisoquinolines
Alternative Parents
Substituents
  • Benzylisoquinoline
  • Diaryl ether
  • Tetrahydroisoquinoline
  • Methoxyphenol
  • Anisole
  • Aralkylamine
  • Alkyl aryl ether
  • Benzenoid
  • Quaternary ammonium salt
  • Tertiary aliphatic amine
  • Tertiary amine
  • Oxacycle
  • Azacycle
  • Ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Organic cation
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationUsed as a diagnosis agent for myasthenia gravis, and also to facilitate the intubation after induction of anesthesia in surgical procedure
PharmacodynamicsTubocurarine, a naturally occurring alkaloid, is used to treat smoking withdrawl syndrom.
Mechanism of actionTubocurarine, the chief alkaloid in tobacco products, binds stereo-selectively to nicotinic-cholinergic receptors at the autonomic ganglia, in the adrenal medulla, at neuromuscular junctions, and in the brain. Two types of central nervous system effects are believed to be the basis of Tubocurarine's positively reinforcing properties. A stimulating effect is exerted mainly in the cortex via the locus ceruleus and a reward effect is exerted in the limbic system. At low doses the stimulant effects predominate while at high doses the reward effects predominate. Intermittent intravenous administration of Tubocurarine activates neurohormonal pathways, releasing acetylcholine, norepinephrine, dopamine, serotonin, vasopressin, beta-endorphin, growth hormone, and ACTH.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half life1-2 hours
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.9757
Blood Brain Barrier+0.7287
Caco-2 permeable+0.6869
P-glycoprotein substrateSubstrate0.8917
P-glycoprotein inhibitor INon-inhibitor0.8855
P-glycoprotein inhibitor IINon-inhibitor0.8385
Renal organic cation transporterNon-inhibitor0.6081
CYP450 2C9 substrateNon-substrate0.8397
CYP450 2D6 substrateNon-substrate0.6012
CYP450 3A4 substrateSubstrate0.6597
CYP450 1A2 substrateNon-inhibitor0.9365
CYP450 2C9 inhibitorNon-inhibitor0.948
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9136
CYP450 3A4 inhibitorNon-inhibitor0.9284
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9794
Ames testNon AMES toxic0.5666
CarcinogenicityNon-carcinogens0.9195
BiodegradationNot ready biodegradable0.9401
Rat acute toxicity2.6331 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8786
hERG inhibition (predictor II)Non-inhibitor0.5444
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Solutionintravenous3 mg
Solutionintramuscular; intravenous3 mg
Prices
Unit descriptionCostUnit
Tubocurarine cl 3 mg/ml vial0.37USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.000323 mg/mLALOGPS
logP3.12ALOGPS
logP3.14ChemAxon
logS-6.3ALOGPS
pKa (Strongest Acidic)6.45ChemAxon
pKa (Strongest Basic)8.12ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area80.62 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity187.06 m3·mol-1ChemAxon
Polarizability66.41 Å3ChemAxon
Number of Rings7ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesM03AA02
AHFS Codes
  • 12:20.00
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (73.2 KB)
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with 1,10-Phenanthroline.
4-AndrostenedioneThe risk or severity of adverse effects can be increased when 4-Androstenedione is combined with Tubocurarine.
AcebutololTubocurarine may increase the bradycardic activities of Acebutolol.
AcetylcholineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Acetylcholine.
AclidiniumAclidinium may increase the anticholinergic activities of Tubocurarine.
AclidiniumThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Aclidinium.
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Tubocurarine.
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Tubocurarine.
AlfentanilThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Alfentanil.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Alphacetylmethadol.
AlprenololTubocurarine may increase the bradycardic activities of Alprenolol.
AmbenoniumThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Ambenonium.
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Tubocurarine.
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Tubocurarine.
ArecolineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Arecoline.
ArotinololTubocurarine may increase the bradycardic activities of Arotinolol.
AtenololTubocurarine may increase the bradycardic activities of Atenolol.
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Tubocurarine.
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Tubocurarine.
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Tubocurarine.
BefunololTubocurarine may increase the bradycardic activities of Befunolol.
BenactyzineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Benactyzine.
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Tubocurarine.
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Tubocurarine.
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Tubocurarine.
BetaxololTubocurarine may increase the bradycardic activities of Betaxolol.
BethanecholThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Bethanechol.
BevantololTubocurarine may increase the bradycardic activities of Bevantolol.
BezitramideThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Bezitramide.
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Tubocurarine.
BisoprololTubocurarine may increase the bradycardic activities of Bisoprolol.
BopindololTubocurarine may increase the bradycardic activities of Bopindolol.
Botulinum Toxin Type ATubocurarine may increase the anticholinergic activities of Botulinum Toxin Type A.
Botulinum Toxin Type BTubocurarine may increase the anticholinergic activities of Botulinum Toxin Type B.
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Tubocurarine.
BufuralolTubocurarine may increase the bradycardic activities of Bufuralol.
BupranololTubocurarine may increase the bradycardic activities of Bupranolol.
BuprenorphineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Buprenorphine.
ButorphanolThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Butorphanol.
CarbacholThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Carbachol.
CarfentanilThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Carfentanil.
CarteololTubocurarine may increase the bradycardic activities of Carteolol.
CarvedilolTubocurarine may increase the bradycardic activities of Carvedilol.
CeliprololTubocurarine may increase the bradycardic activities of Celiprolol.
CevimelineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Cevimeline.
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Tubocurarine.
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Chlorphenoxamine.
ChlorthalidoneThe serum concentration of Chlorthalidone can be increased when it is combined with Tubocurarine.
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Tubocurarine.
CimetropiumTubocurarine may increase the anticholinergic activities of Cimetropium.
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Tubocurarine.
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Tubocurarine.
CodeineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Codeine.
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Tubocurarine.
CoumaphosThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Coumaphos.
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Tubocurarine.
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Tubocurarine.
DecamethoniumThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Decamethonium.
DehydroepiandrosteroneThe risk or severity of adverse effects can be increased when Dehydroepiandrosterone is combined with Tubocurarine.
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Tubocurarine.
DemecariumThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Demecarium.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Tubocurarine.
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Tubocurarine.
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Tubocurarine.
DexamethasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Tubocurarine.
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Tubocurarine.
DexetimideThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Dexetimide.
DextromoramideThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Dextropropoxyphene.
DezocineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Dezocine.
DichlorvosThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Dichlorvos.
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Tubocurarine.
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Tubocurarine.
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Tubocurarine.
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Tubocurarine.
DihydrocodeineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Dihydrocodeine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Dihydromorphine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Diphenoxylate.
DipyridamoleThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Dipyridamole.
DonepezilThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Donepezil.
DPDPEThe risk or severity of adverse effects can be increased when Tubocurarine is combined with DPDPE.
DronabinolTubocurarine may increase the tachycardic activities of Dronabinol.
EchothiophateThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Echothiophate.
EdrophoniumThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Edrophonium.
EluxadolineTubocurarine may increase the constipating activities of Eluxadoline.
EPIBATIDINEThe risk or severity of adverse effects can be increased when Tubocurarine is combined with EPIBATIDINE.
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Tubocurarine.
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Tubocurarine.
EsmololTubocurarine may increase the bradycardic activities of Esmolol.
EstroneThe risk or severity of adverse effects can be increased when Estrone is combined with Tubocurarine.
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Tubocurarine.
EthylmorphineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Ethylmorphine.
EtorphineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Etorphine.
FentanylThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Fentanyl.
FenthionThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Fenthion.
FesoterodineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Fesoterodine.
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Tubocurarine.
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Tubocurarine.
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with Tubocurarine.
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Tubocurarine.
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Tubocurarine.
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Tubocurarine.
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Tubocurarine.
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Tubocurarine.
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Tubocurarine.
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Tubocurarine.
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Tubocurarine.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Tubocurarine.
GalantamineThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Galantamine.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Tubocurarine.
Ginkgo bilobaThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Ginkgo biloba.
Glucagon recombinantThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Glucagon recombinant.
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Tubocurarine.
GlycopyrroniumTubocurarine may increase the anticholinergic activities of Glycopyrronium.
GTS-21The risk or severity of adverse effects can be increased when Tubocurarine is combined with GTS-21.
HeroinThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Heroin.
HexamethoniumThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Hexamethonium.
HomatropineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Homatropine.
Huperzine AThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Huperzine A.
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Tubocurarine.
HydrocodoneThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Hydrocodone.
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Tubocurarine.
HydroflumethiazideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Tubocurarine.
HydromorphoneThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Hydromorphone.
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Tubocurarine.
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Tubocurarine.
IndenololTubocurarine may increase the bradycardic activities of Indenolol.
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Tubocurarine.
IsoflurophateThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Isoflurophate.
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Tubocurarine.
KetobemidoneThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Ketobemidone.
LabetalolTubocurarine may increase the bradycardic activities of Labetalol.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Levomethadyl Acetate.
LevorphanolThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Levorphanol.
LobelineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Lobeline.
LofentanilThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Lofentanil.
MalathionThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Malathion.
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Tubocurarine.
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Tubocurarine.
MefloquineThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Mefloquine.
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Tubocurarine.
MemantineThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Memantine.
MethacholineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Methacholine.
MethadoneThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Methadyl Acetate.
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Tubocurarine.
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Tubocurarine.
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Tubocurarine.
MetixeneThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Metixene.
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Tubocurarine.
MetoprololTubocurarine may increase the bradycardic activities of Metoprolol.
MianserinMianserin may increase the anticholinergic activities of Tubocurarine.
MinaprineThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Minaprine.
MirabegronThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Mirabegron.
MivacuriumTubocurarine may decrease the neuromuscular blocking activities of Mivacurium.
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with Tubocurarine.
MorphineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Morphine.
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when Tubocurarine is combined with N-butylscopolammonium bromide.
NabiloneTubocurarine may increase the tachycardic activities of Nabilone.
NadololTubocurarine may increase the bradycardic activities of Nadolol.
NalbuphineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Nalbuphine.
NeostigmineThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Neostigmine.
NicotineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Nicotine.
Nicotine bitartrateThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Nicotine bitartrate.
NormethadoneThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Normethadone.
NVA237The risk or severity of adverse effects can be increased when Tubocurarine is combined with NVA237.
OpiumThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Opium.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Tubocurarine.
OxprenololTubocurarine may increase the bradycardic activities of Oxprenolol.
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Tubocurarine.
OxycodoneThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Oxycodone.
OxymorphoneThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Oxymorphone.
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Tubocurarine.
PancuroniumThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Pancuronium.
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Tubocurarine.
PenbutololTubocurarine may increase the bradycardic activities of Penbutolol.
PentazocineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Pentazocine.
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Tubocurarine.
PethidineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Pethidine.
PhysostigmineThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Physostigmine.
PilocarpineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Pilocarpine.
PindololTubocurarine may increase the bradycardic activities of Pindolol.
PipecuroniumThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Pipecuronium.
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Tubocurarine.
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Tubocurarine.
Potassium ChlorideTubocurarine may increase the ulcerogenic activities of Potassium Chloride.
PractololTubocurarine may increase the bradycardic activities of Practolol.
PramlintidePramlintide may increase the anticholinergic activities of Tubocurarine.
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Tubocurarine.
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Tubocurarine.
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Tubocurarine.
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Tubocurarine.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Tubocurarine.
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Tubocurarine.
PropranololTubocurarine may increase the bradycardic activities of Propranolol.
PyridostigmineThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Pyridostigmine.
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Tubocurarine.
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Tubocurarine.
RamosetronTubocurarine may increase the constipating activities of Ramosetron.
RapacuroniumTubocurarine may decrease the neuromuscular blocking activities of Rapacuronium.
RemifentanilThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Remifentanil.
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Tubocurarine.
RivastigmineThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Rivastigmine.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tubocurarine.
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Scopolamine butylbromide.
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Tubocurarine.
SolifenacinThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Solifenacin.
SotalolTubocurarine may increase the bradycardic activities of Sotalol.
SuccinylcholineThe serum concentration of Succinylcholine can be increased when it is combined with Tubocurarine.
SufentanilThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Sufentanil.
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Tubocurarine.
TacrineThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Tacrine.
TapentadolThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Tapentadol.
TimololTubocurarine may increase the bradycardic activities of Timolol.
TiotropiumTubocurarine may increase the anticholinergic activities of Tiotropium.
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Tubocurarine.
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Tubocurarine.
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Tubocurarine.
TopiramateThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Tramadol.
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Tubocurarine.
TrichlorfonThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Trichlorfon.
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Tubocurarine.
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Tubocurarine.
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Tubocurarine.
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Tubocurarine.
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Tubocurarine.
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Tubocurarine.
UmeclidiniumThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Umeclidinium.
VareniclineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Varenicline.
VecuroniumThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Vecuronium.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Drug binding
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name:
CHRNA2
Uniprot ID:
Q15822
Molecular Weight:
59764.82 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Wenningmann I, Dilger JP: The kinetics of inhibition of nicotinic acetylcholine receptors by (+)-tubocurarine and pancuronium. Mol Pharmacol. 2001 Oct;60(4):790-6. [PubMed:11562442 ]
  4. Nishimura K, Kitamura Y, Taniguchi T, Agata K: Analysis of motor function modulated by cholinergic neurons in planarian Dugesia japonica. Neuroscience. 2010 Jun 16;168(1):18-30. doi: 10.1016/j.neuroscience.2010.03.038. Epub 2010 Mar 23. [PubMed:20338223 ]
  5. Jonsson Fagerlund M, Dabrowski M, Eriksson LI: Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52. doi: 10.1097/ALN.0b013e31819fade3. [PubMed:19417616 ]
  6. Liu M, Dilger JP: Synergy between pairs of competitive antagonists at adult human muscle acetylcholine receptors. Anesth Analg. 2008 Aug;107(2):525-33. doi: 10.1213/ane.0b013e31817b4469. [PubMed:18633030 ]
  7. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Voltage-gated potassium channel activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gated ion channel, which when activated causes fast, depolarizing responses in neurons. It is a cation-specific, but otherwise relatively nonselective, ion channel.
Gene Name:
HTR3A
Uniprot ID:
P46098
Molecular Weight:
55279.835 Da
References
  1. Hefft S, Hulo S, Bertrand D, Muller D: Synaptic transmission at nicotinic acetylcholine receptors in rat hippocampal organotypic cultures and slices. J Physiol. 1999 Mar 15;515 ( Pt 3):769-76. [PubMed:10066903 ]
  2. Yan D, White MM: Interaction of d-tubocurarine analogs with mutant 5-HT(3) receptors. Neuropharmacology. 2002 Sep;43(3):367-73. [PubMed:12243766 ]
  3. Yan D, Meyer JK, White MM: Mapping residues in the ligand-binding domain of the 5-HT(3) receptor onto d-tubocurarine structure. Mol Pharmacol. 2006 Aug;70(2):571-8. Epub 2006 May 24. [PubMed:16723497 ]
  4. Peters JA, Malone HM, Lambert JJ: Antagonism of 5-HT3 receptor mediated currents in murine N1E-115 neuroblastoma cells by (+)-tubocurarine. Neurosci Lett. 1990 Mar 2;110(1-2):107-12. [PubMed:1691468 ]
  5. Emerit MB, Riad M, Fattaccini CM, Hamon M: Characteristics of [14C]guanidinium accumulation in NG 108-15 cells exposed to serotonin 5-HT3 receptor ligands and substance P. J Neurochem. 1993 Jun;60(6):2059-67. [PubMed:7684066 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Serine hydrolase activity
Specific Function:
Terminates signal transduction at the neuromuscular junction by rapid hydrolysis of the acetylcholine released into the synaptic cleft. Role in neuronal apoptosis.
Gene Name:
ACHE
Uniprot ID:
P22303
Molecular Weight:
67795.525 Da
References
  1. Radic Z, Taylor P: The influence of peripheral site ligands on the reaction of symmetric and chiral organophosphates with wildtype and mutant acetylcholinesterases. Chem Biol Interact. 1999 May 14;119-120:111-7. [PubMed:10421444 ]
  2. Golicnik M, Fournier D, Stojan J: Acceleration of Drosophila melanogaster acetylcholinesterase methanesulfonylation: peripheral ligand D-tubocurarine enhances the affinity for small methanesulfonylfluoride. Chem Biol Interact. 2002 Feb 20;139(2):145-57. [PubMed:11823003 ]
  3. Radic Z, Taylor P: Peripheral site ligands accelerate inhibition of acetylcholinesterase by neutral organophosphates. J Appl Toxicol. 2001 Dec;21 Suppl 1:S13-4. [PubMed:11920914 ]
  4. Gupta RC, Dettbarn WD: Potential of memantine, D-tubocurarine, and atropine in preventing acute toxic myopathy induced by organophosphate nerve agents: soman, sarin, tabun and VX. Neurotoxicology. 1992 Fall;13(3):649-61. [PubMed:1475066 ]
  5. Bianchi DA, Hirschmann GS, Theoduloz C, Bracca AB, Kaufman TS: Synthesis of tricyclic analogs of stephaoxocanidine and their evaluation as acetylcholinesterase inhibitors. Bioorg Med Chem Lett. 2005 Jun 2;15(11):2711-5. [PubMed:15878275 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Secondary active organic cation transmembrane transporter activity
Specific Function:
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnicotinamide (NMN), 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP), the endogenous compounds choline, guanidine, histamine, epinephrine, adrenaline, noradrenaline and dopamine, and the drugs quinine...
Gene Name:
SLC22A1
Uniprot ID:
O15245
Molecular Weight:
61153.345 Da
References
  1. Busch AE, Quester S, Ulzheimer JC, Waldegger S, Gorboulev V, Arndt P, Lang F, Koepsell H: Electrogenic properties and substrate specificity of the polyspecific rat cation transporter rOCT1. J Biol Chem. 1996 Dec 20;271(51):32599-604. [PubMed:8955087 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Quaternary ammonium group transmembrane transporter activity
Specific Function:
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creatinine, amantadine, memantine, acriflavine, 4-[4-(dimethylamino)-styryl]-N-methylpyridinium ASP, amiloride, metformin, N-1-methylnicotinamide (NMN), tetraethylammonium (TEA), 1-methyl-4-phenylpyridiniu...
Gene Name:
SLC22A2
Uniprot ID:
O15244
Molecular Weight:
62579.99 Da
References
  1. Gorboulev V, Ulzheimer JC, Akhoundova A, Ulzheimer-Teuber I, Karbach U, Quester S, Baumann C, Lang F, Busch AE, Koepsell H: Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol. 1997 Jul;16(7):871-81. [PubMed:9260930 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23